MedPath

The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism

Phase 4
Completed
Conditions
Hypogonadism
Interventions
Registration Number
NCT02111473
Lead Sponsor
Gulhane School of Medicine
Brief Summary

The study is designed to answer the following questions:

1) What is the effect of testosteron replacement treatment on the endothelial dysfunction.

2/ What is the effect of testosteron replacement on the bone mineral metabolism.

Detailed Description

this is an interventional study which is examine the effect of testosteron replacement treatment on the endothelial dysfunction and bone mineral metabolism in hypogonadotropic hypogonadal patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
49
Inclusion Criteria
  • Men
  • Congenital hypogonadism
  • Treatment Naive
Exclusion Criteria
  • Previous history of androgen replacement
  • Hypertension
  • Diabetes mellitus

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
testosteroneTestosteronetestosterone 250 mg injection per 3-4 weeks for 6 months
Primary Outcome Measures
NameTimeMethod
the effect of testosteron replacement treatment on the Fibroblast Growth Factor-23.6 months

Plasma FGF-23 levels were determined by ELISA, (Human Intact FGF-23 ELISA Kit, Inc., San Clement, CA, USA).

the effect of testosteron replacement treatment on the asymmetric dimethylarginine.6 months

Plasma ADMA levels were determined by ELISA (Immunodiagnostic, Bernheim, Germany)

the effect of testosteron replacement treatment on the vitamin D levels.6 months.

Plasma 25-OH vitamin D3 levels were measured by Immuchrom kits (Hessen, Germany) using isocratic HPLC method with UV detector in Prominence HPLC system.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Gulhane School of Medicine

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath